BioMedNewsBreaks

WednesdayJan 13, 2021 11:27 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Passes Final Release Tests for Manufacturing Run of Proprietary Immunogene Therapy Treatment

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that it has achieved a significant milestone for its REQORSA(TM) Immunogene Therapy. The company has met all specifications and passed all final release tests for its initial scaled-up, clinical-grade manufacturing run of REQORSA(TM) immunogene therapy. This achievement comes in advance of GNPX’s upcoming Acclaim-1 and Acclaim-2 clinical trials for the treatment of non-small cell lung cancer (“NSCLC”). This announcement also follows the company’s successful completion of the technology transfer of the manufacturing process for the production of REQORSA from the major…

Continue Reading

WednesdayJan 13, 2021 11:24 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Initiates Program to Identify UK, South African COVID Sequences

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has started a series of studies required by the FDA for Emergency Use Authorization (“EUA”) testing for its COVID-19 assay in a point-of-care (“POC”) environment using its fully automated MiQLab(TM) system. “I’m excited we have progressed to the point where we have started our FDA study. Our open-access technology is unlike any other on the market today, as it could be configured quickly to detect new variants, such as the recent UK variant 1 (aka SARS-CoV-2 VUI 202012/01),”…

Continue Reading

WednesdayJan 13, 2021 11:02 am

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTC: IMEXF) Engages IBN, Builds Momentum for 2021

Imagin Medical (CSE: IME) (OTC: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced it has selected the corporate communications expertise of the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. Under the partnership, IBN will leverage its investor-based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Imagin Medical. Like most companies during 2020, Imagin had to adapt to the unexpected circumstances surrounding…

Continue Reading

WednesdayJan 13, 2021 10:32 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Appoints Diabetes, Behavioral Health Experts to Scientific Advisory Board

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced the appointment of two renowned experts to its Scientific Advisory Board (“SAB”). Dr. Marilyn Ritholz, psychologist at Joslin Diabetes Center, a Harvard Medical School affiliate, and Dr. David Horwitz, former global chief medical officer of Johnson & Johnson Diabetes Institute, join SAB chairman Eric Milledge; the prestigious board is focused on advancing Dario's technical leadership, helping to guide the development of the company’s bold technology road map and advancing Dario's DTx (“DTx”) platform by integrating members' comprehensive experience and expertise into the company offering. Ritholz and Horwitz are recognized…

Continue Reading

WednesdayJan 13, 2021 9:46 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on C3 Chat Show Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent C3 Chat Show Podcast. The podcast, hosted by Sid Vaidya and Eric Gershey, explores topics related to entrepreneurship, life experiences and best practices. During his interview, Climaco shared the history of CNS Pharmaceuticals and provided an update on the company’s recent business progress, including the fact that the company recently received FDA approval to begin clinical trials studying the company’s lead drug candidate, Berubicin. CNSP is developing Berubicin as a potential treatment for glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Climaco called Berubicin…

Continue Reading

TuesdayJan 12, 2021 12:58 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Focuses on Multi-Omic Approach to Personalized Treatment Options

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is building a business around an emerging approach to disease prevention and treatment that identifies the variability in genes, environment and lifestyle for each individual, and then uses that information to provide individualized treatments designed to ultimately improve patient outcomes. A recent article discussing this reads, “POAI realizes that ‘just genomics’ is not enough to deliver personalized therapeutic options. The company believes that a multi-omic approach to disease, or one that gathers data from…

Continue Reading

TuesdayJan 12, 2021 11:47 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX), First Wave, Receive Notice of Allowance for Niclosamide Patent

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, announced that it, along with First Wave Bio Inc., has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”). The notice of allowance is for issuance of a patent that covers use of niclosamide as a treatment for COVID-19-associated GI disease. AZRX filed the patent with First Wave, a clinical-stage biotechnology company developing novel gut-targeted small molecules for inflammatory bowel disease and other serious conditions. GI infections have become a significant unmet clinical need during the…

Continue Reading

MondayJan 11, 2021 1:23 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at H.C. Wainwright BIOCONNECT 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. According to the update, the presentation is now available for on-demand listening by visiting https://ibn.fm/OVOdD. In addition, the press release can also be viewed on the company’s website. To view the full press release, visit https://ibn.fm/4nMa4 About Processa Pharmaceuticals Inc. The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical…

Continue Reading

MondayJan 11, 2021 12:10 pm

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at the Biotech Showcase(TM) Digital 2021 Conference

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at the Biotech Showcase(TM) Digital 2021 Conference. According to the update, the conference is taking place online between January 11-15 and will feature prerecorded sessions of company presentations. Dr. James Woody, Chief Executive Officer, will provide an overview of 180 Life Sciences and the company’s progress in key programs. In addition, 180 Life Sciences will host one-on-one meetings with investors and…

Continue Reading

FridayJan 08, 2021 12:22 pm

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) COO Shines the Spotlight on Proprietary Tech, Unique Value Proposition

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an innovative agriculture biotech company focused on providing natural biological protection for high value crops, was featured in a recent SmallCap-Investor interview. The company’s COO Colin Bletsky joined the interview to discuss MustGrow and its unique value proposition and ambitious plans for the future. Bletsky explained that a rigorous scientific process stands behind MustGrow’s proprietary technology, in which the company has invested more than $10 million. MustGrow has also conducted an estimated 110 studies in the field and worked with third-party companies, leading to the ownership of approximately 100 patents The company is…

Continue Reading